

## **ABSTRACT TEMPLATE for Company Presentations**

The maximum number of words for this abstract is 300 words.

You may delete the section instructions, leaving only the bolded bullet title.

**Questions for categories: Biotech/Pharma or Medical Devices or Health IT/Digital**

**Answers should not exceed 60 words per question**

- **Investment Rational**  
Co-founded by Prof. Moshe Shoham, founder of Mazor Robotics, Tamar's endoscopic robotic system is geared to "small cavity" procedures in Neurosurgery, Spine, Urology, and more – representing a \$60B market opportunity annually. Millions of patients cannot benefit from robotic surgery due to the technological limitations of current robots. Initial human testing will be focused on for pituitary tumor removal.
- **Business Strategy**  
Tamar will build its robotic platform into the leading robotic system for small cavity procedures where the current multi and single-port systems cannot be used. The company plans to initially sell its system to a limited number of academic Neurosurgical centers and, following initial installations and ongoing utilization, partner with a large player to expand the market.
- **Core Technology**  
Current single port robotic systems require large working spaces due to their "arm and elbows" kinematics, limiting their use primarily in abdominal, thoracic and GYN surgery. Based on innovative kinematics, Tamar's system enables accurate and safe robotic surgery in highly challenging workspaces where robotics currently cannot be used offering improved clinical and economic benefits for millions of procedures annually worldwide.
- **Product Profile/Pipeline**  
Tamar's system will initially be used in Neurosurgery where the use of robotic systems is highly limited. The system will then be offered for use in additional surgical domains where it will offer substantially value (based on conducted primary market research). FIH testing will be focused on pituitary tumor removal. A leading and active international SAB supports the company's activities.
- **What's Next?**  
R&D – complete clinical system, lab testing  
Preclinical / Clinicals - cadaver studies, FIH testing  
Organizational Plans – expand R&D and clinical/regulatory team, pre-sub with FDA  
Financial Plans – Series A round (underway)